BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2026-02
155 industry Phase 2/3 trial readout(s) and 42 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-02 est. | P3 | Zensun Sci. & Tech. Co., Ltd. | NCT03388593 Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. | Chronic Heart Failure | unknown | 1600 |
| 2026-02 est. | P3 | Can-Fite BioPharma CANF | NCT05201404 Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis | Hepatocellular Carcinoma; Cirrhosis | recruiting | 471 |
| 2026-02 est. | P2 | Marinus Pharmaceuticals | NCT05757544 Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE) | Status Epilepticus | withdrawn | |
| 2026-02 est. | P1/P2 | SignPath Pharma, Inc. | NCT05768919 Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas | Glioblastoma | recruiting | 30 |
| 2026-02 est. | P2 | Shanghai Henlius Biotech | NCT05787613 A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previousl | NSCLC Stage IV | active not recruiting | 132 |
| 2026-02 est. | P1/P2 | Beijing Tide Pharmaceutical Co., Ltd | NCT06169722 TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD)) | GVHD, Chronic | active not recruiting | 60 |
| 2026-02 est. | P3 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | NCT06182592 A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia | High-risk (Secondary) Acute Myeloid Leukemia | unknown | 120 |
| 2026-02 est. | P1/P2 | Beijing Mabworks Biotech Co., Ltd. | NCT06232096 A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. | Relapsed or Refractory Multiple Myeloma | recruiting | 154 |
| 2026-02 est. | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT06237413 A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours | Solid Tumor; KRAS Mutation-Related Tumors | unknown | 110 |
| 2026-02 est. | P2 | HRYZ Biotech Co. | NCT06277154 MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | Leiomyosarcoma; Liposarcoma; Synovial Sarcoma; Angiosarcoma; Undifferentiated Pleomorphic Sarcoma; E | recruiting | 148 |
| 2026-02 est. | P2 | Lallemand Health Solutions | NCT06385054 Effect of Probiotics on Infantile Colic Symptoms | Infantile Colic | recruiting | 70 |
| 2026-02 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06430437 A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations | Non-Small Cell Lung Cancer With HER2- Mutations | recruiting | 300 |
| 2026-02 est. | P2 | Alto Neuroscience ANRO | NCT06502964 Study of ALTO-101 in Patients With Schizophrenia | Schizophrenia; Cognitive Impairment | recruiting | 82 |
| 2026-02 est. | P3 | Hasten Biopharmaceutical Co., Ltd. | NCT06568471 A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia | Hypercholesterolemia; Dyslipidemias; Primary Hypercholesterolemia; Heterozygous Familial Hypercholes | recruiting | 210 |
| 2026-02 est. | P2 | EnnovaBio | NCT06632613 Efficacy and Safety of ENN0403 in Patients At High Risk for Acute Kidney Injury Following Elective Cardiac Surgery | Cardiac Surgery Associated - Acute Kidney Injury | unknown | 200 |
| 2026-02 est. | P2 | Biocad | NCT06668792 An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | recruiting | 100 |
| 2026-02 est. | P2/P3 | Veradermics, Inc. MANE | NCT06724614 Efficacy and Safety of VDPHL01 in Males With AGA | Androgenetic Alopecia; AGA; Male Pattern Baldness | active not recruiting | 480 |
| 2026-02 est. | P3 | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | NCT06766357 A Study of the Efficacy and Safety of Cyclosporin Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease | Moderate to Severe Dry Eye | recruiting | 360 |
| 2026-02 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT07018453 A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs | Type 2 Diabetes Mellitus | active not recruiting | 173 |
| 2026-02 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT07051486 A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer | Recurrent or Metastatic Cervical Cancer | recruiting | 60 |
| 2026-02 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT07102888 A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis | Plaque Psoriasis in Children; Plaque Psoriasis in Adolescents | not yet recruiting | 20 |
| 2026-02 est. | P2 | Telios Pharma, Inc. | NCT07220408 Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis | Allergic Conjunctivitis | recruiting | 60 |
| 2026-02 est. | P1/P2 | Wandercraft | NCT07220733 Safety and Feasibility of a Self-Balancing Exoskeleton for Rehabilitation in the Thoracic Surgical Intensive Care Unit: a Pilot Trial | Critical Illness; Post Operative Complication; Thoracic Surgery | recruiting | 5 |
| 2026-02 est. | P2 | Propedix, Inc. | NCT07245667 Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study | Tinea Pedis | recruiting | 150 |
| 2026-02 est. | P2 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | NCT07311369 Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery | Moderate to Severe Acute Postoperative Pain | recruiting | 40 |
| 2026-02 est. | P2 | Eirion Therapeutics Inc. | NCT07321834 A Study to Evaluate AI-09 In Participants With Glabellar Lines | Glabellar Lines | active not recruiting | 68 |
| 2026-02 est. | P2 | Anhui Palo Alto Pharmaceuticals, Inc. | NCT07326995 Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma | Bronchial Asthma | recruiting | 60 |
| 2026-02-01 | P3 | Tasly Pharmaceutical Group Co., Ltd | NCT06068465 A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis | Parkinson's Disease Psychosis | completed | 248 |
| 2026-02-01 est. | P2 | MedRegen LLC | NCT06308926 MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients | Acute Respiratory Distress Syndrome; Respiratory Failure; Respiratory Distress Syndrome; Respiratory | unknown | 60 |
| 2026-02-01 est. | P1/P2 | Chengdu Zenitar Biomedical Technology Co., Ltd | NCT06484829 Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Multiple Myeloma (RRMM) | recruiting | 144 |
| 2026-02-01 | P2 | Regeneron Pharmaceuticals REGN | NCT06608901 A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension | Sepsis-Induced Hypotension | completed | 76 |
| 2026-02-01 | P2 | Aurigene Discovery Technologies Limited | NCT06760702 A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers | Ovarian Cancer; Colorectal Cancer; Renal Cancer | terminated | 29 |
| 2026-02-01 | P3 | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT06980272 SSGJ-707 in Advanced Non-Small Cell Lung Cancer | Advanced Non-Small Cell Lung Cancer | terminated | 3 |
| 2026-02-02 | P3 | Merck Sharp & Dohme LLC MRK | NCT04586231 A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | Carcinoma, Renal Cell | active not recruiting | 747 |
| 2026-02-02 | P3 | United Therapeutics UTHR | NCT04708782 Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease | completed | 598 |
| 2026-02-02 | P2 | Pfizer PFE | NCT05926960 A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma | Melanoma | terminated | 38 |
| 2026-02-02 | P1/P2 | Synartro AB | NCT06989645 A Phase 1/2a Study to Evaluate Single Intraarticular Injections of 3 Dose Levels of SYN321 and Placebo in Patients With Symptomatic Knee Osteoarthritis | Osteoarthritis of Knee | completed | 35 |
| 2026-02-03 | P2 | Seagen, a wholly owned subsidiary of Pfizer | NCT04609566 Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | Melanoma; Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck | completed | 161 |
| 2026-02-03 | P3 | Immunovant Sciences GmbH IMVT | NCT05524571 Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease | Thyroid Eye Disease | completed | 86 |
| 2026-02-03 | P2 | Novartis Pharmaceuticals NVS | NCT05592990 A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy | Achilles Tendinopathy | completed | 45 |
| 2026-02-03 | P1/P2 | Ocugen OCGN | NCT06018558 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy | Geographic Atrophy | active not recruiting | 60 |
| 2026-02-03 | P3 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | NCT06235086 A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | completed | 632 |
| 2026-02-03 | P1/P2 | Boehringer Ingelheim | NCT06515002 A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1) | Cystic Fibrosis | terminated | 5 |
| 2026-02-04 | P3 | Merck Sharp & Dohme LLC MRK | NCT04736706 A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination Wit | Carcinoma, Renal Cell | active not recruiting | 1688 |
| 2026-02-04 | P3 | Anthos Therapeutics, Inc. | NCT05171049 A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE | Venous Thromboembolism; Deep Venous Thrombosis; Pulmonary Embolism | terminated | 1150 |
| 2026-02-04 | P2 | Janssen Research & Development, LLC | NCT05250973 A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis | Amyloidosis | active not recruiting | 151 |
| 2026-02-04 | P3 | AbbVie ABBV | NCT05411198 Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years o | Open-Angle Glaucoma | completed | 74 |
| 2026-02-04 | P3 | Merck Sharp & Dohme LLC MRK | NCT05899049 A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination Wit | Carcinoma, Renal Cell | active not recruiting | 251 |
| 2026-02-04 | P2 | AstraZeneca AZN | NCT06529419 A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations | Asthma | completed | 537 |
| 2026-02-05 | P3 | Pfizer PFE | NCT05583526 A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo | Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo | completed | 607 |
| 2026-02-05 | P2/P3 | AbbVie ABBV | NCT06547125 A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Qual | Skin Quality Deficit | completed | 135 |
| 2026-02-05 | P3 | Daewoong Pharmaceutical Co. LTD. | NCT06671392 A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension | Essential Hypertension | completed | 198 |
| 2026-02-06 | P3 | Forma Therapeutics, Inc. | NCT04624659 A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) | Sickle Cell Disease | active not recruiting | 450 |
| 2026-02-06 | P3 | Janssen Research & Development, LLC | NCT05754957 A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome | Acute Coronary Syndrome | completed | 14194 |
| 2026-02-06 | P1/P2 | Innate Pharma IPHA | NCT06088654 Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | Non Hodgkin Lymphoma | terminated | 23 |
| 2026-02-06 | P3 | UCB Biopharma SRL | NCT06624228 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis | Psoriatic Arthritis | completed | 553 |
| 2026-02-06 est. | P2 | Therakos LLC | NCT06646016 EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis | Immune-related Colitis | withdrawn | |
| 2026-02-06 est. | P2 | Shanghai Auzone Biological Technology Co., Ltd. | NCT06757504 Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD | Autism Spectrum Disorder (ASD) | recruiting | 150 |
| 2026-02-07 est. | P3 | Gan & Lee Pharmaceuticals. | NCT06767748 A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin | Diabetes | active not recruiting | 620 |
| 2026-02-08 | P1/P2 | Nanjing Immunophage Biotech Co., Ltd | NCT05142592 Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors | Safety Issues; Tolerability; Pharmacokinetics | completed | 34 |
| 2026-02-09 | P2 | Rhythm Pharmaceuticals, Inc. RYTM | NCT06046443 A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity | Hypothalamic Obesity | completed | 28 |
| 2026-02-09 | P2 | Pfizer PFE | NCT06531538 A Study to Learn About How a New Pneumococcal Vaccine Works in Children | Pneumococcal Disease | completed | 225 |
| 2026-02-09 | P2 | Chengdu Diao Jiuhong Pharmaceutical Factory | NCT06822946 Zhibitai Capsules for the Treatment of Primary Hyperlipidemia | Primary Hyperlipidemia | completed | 201 |
| 2026-02-09 | P2 | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | NCT07101120 A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder | Major Depressive Disorder (MDD) | completed | 126 |
| 2026-02-10 | P3 | PTC Therapeutics PTC | NCT01247207 Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) | Duchenne Muscular Dystrophy | terminated | 265 |
| 2026-02-10 | P2 | Sanofi SNY | NCT05588843 Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis | Colitis Ulcerative | active not recruiting | 187 |
| 2026-02-10 | P2 | Intercept Pharmaceuticals | NCT05639543 FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study | Alcohol Associated Hepatitis | terminated | 67 |
| 2026-02-10 est. | P2 | Eagle Pharmaceuticals, Inc. EXP | NCT05776004 Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia | Pneumonia, Bacterial | active not recruiting | 276 |
| 2026-02-10 | P2 | Biogen BIIB | NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing For | Relapsing Forms of Multiple Sclerosis | completed | 127 |
| 2026-02-10 est. | P2 | Guangzhou JOYO Pharma Co., Ltd | NCT06158490 A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis | Moderate-to-severe Atopic Dermatitis | enrolling by invitation | 120 |
| 2026-02-10 | P2 | AstraZeneca AZN | NCT06299826 A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure | Chronic Heart Failure | completed | 375 |
| 2026-02-10 | P3 | Intellia Therapeutics NTLA | NCT06634420 HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) | Hereditary Angioedema | active not recruiting | 80 |
| 2026-02-11 | P1/P2 | Xintela AB | NCT05549609 A Study of XSTEM-VLU in Patients With Difficult-to-heal Venous Leg Ulcers | Venous Leg Ulcer | completed | 6 |
| 2026-02-11 | P2 | medac GmbH | NCT06075706 Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease | Steroid-refractory Acute Graft-versus-host Disease | active not recruiting | 49 |
| 2026-02-11 | P3 | Keymed Biosciences Co.Ltd | NCT06424470 Study on the Treatment of Prurigo Nodularis With Stapokibart Injection | Prurigo Nodularis | completed | 200 |
| 2026-02-11 | P3 | Amryt Pharma | NCT06502990 Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy | Generalized Lipodystrophy | terminated | 1 |
| 2026-02-11 | P2 | Astellas Pharma Global Development, Inc. | NCT06812754 A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause | Hot Flashes | completed | 150 |
| 2026-02-11 | P2 | Pancap Pharma Inc. | NCT06949735 Clinical Trial on Digestive Enzymes: Effects on Post-Meal Response to High-Macronutrient Meals | Gastrointestinal Digestion; Healthy; Gastrointestinal Wellbeing; Gastrointestinal Supplements | completed | 24 |
| 2026-02-12 | P3 | Viridian Therapeutics, Inc. VRDN | NCT06625411 An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) | Thyroid Eye Disease | active not recruiting | 132 |
| 2026-02-12 | P2 | Insmed Incorporated INSM | NCT06685835 A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) | Hidradenitis Suppurativa | terminated | 214 |
| 2026-02-12 | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT06764862 Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | completed | 186 |
| 2026-02-12 | P2 | Sanofi SNY | NCT06790121 A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic | Dermatitis Atopic | completed | 150 |
| 2026-02-12 | P3 | Taisho Pharmaceutical Indonesia | NCT07475663 Counterpain PXM Versus Diclofenac Versus Piroxicam | Ankle Sprain; Back Pain; Osteoarthritis (OA) of the Knee; Tennis Elbow; Runner's Knee | completed | 180 |
| 2026-02-13 | P1/P2 | Shire | NCT01887938 An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy | Metachromatic Leukodystrophy (MLD) | completed | 24 |
| 2026-02-13 | P3 | Biohaven Pharmaceuticals, Inc. BHVN | NCT04708834 Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder | Obsessive Compulsive Disorder | terminated | 772 |
| 2026-02-13 | P3 | Boston Scientific Corporation BSX | NCT05016245 MANDARIN (S6371) | Inoperable Hepatocellular Carcinoma | completed | 92 |
| 2026-02-13 | P3 | Epion Therapeutics | NCT06100952 Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus | Keratoconus | completed | 398 |
| 2026-02-13 | P2 | Corcept Therapeutics CORT | NCT06108219 A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) | Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-associated Steatohepatitis (MASH) | completed | 175 |
| 2026-02-13 | P3 | Kodiak Sciences Inc KOD | NCT06270836 A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR) | Diabetic Retinopathy | completed | 255 |
| 2026-02-13 est. | P2 | Tonghua Dongbao Pharmaceutical Co.,Ltd | NCT07036601 Phase II Study of THDBH120 Injection in Overweight or Obese Subjects | Overweight or Obese | recruiting | 276 |
| 2026-02-14 est. | P2 | Convalife (Shanghai) Co., Ltd. | NCT06519110 Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations | Advanced Solid Tumor | unknown | 60 |
| 2026-02-15 | P3 | Beijing Suncadia Pharmaceuticals Co., Ltd | NCT06825416 A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty | Prevention of Arterial and Venous Thrombosis | completed | 1165 |
| 2026-02-15 | P2 | NeuroTherapia, Inc. | NCT07058688 A Study of NTRX-07 in Participants With Alzheimer's Disease | Alzheimer Disease; Mild Cognitive Impairment | completed | 48 |
| 2026-02-15 est. | P1/P2 | Urmila DIwekar | NCT07148999 An Advanced Decision Support Tool for Personalized Medicine for IVF Using Modeling and Optimization for Provera | Infertility (IVF Patients) | recruiting | 200 |
| 2026-02-16 | P3 | Bristol-Myers Squibb BMY | NCT03661320 A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab | Urinary Bladder Neoplasms; Muscle-Invasive Bladder Cancer | completed | 855 |
| 2026-02-16 | P3 | Astellas Pharma Global Development, Inc. | NCT05621616 A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Ne | Neurogenic Detrusor Overactivity | completed | 7 |
| 2026-02-16 | P3 | RDC Clinical Pty Ltd | NCT06444763 Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy Population | Chronic Inflammation; Mobility; Muscle Pain; Joint Pain | completed | 97 |
| 2026-02-16 | P3 | Good Molecules, LLC | NCT07136766 An 18-week Study to Evaluate a Test Product With a Marketed Prescription Product | Hyperpigmentation | completed | 49 |
| 2026-02-16 | P2 | Traws Pharma, Inc. TRAW | NCT07157007 Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 | COVID - 19 | completed | 93 |
| 2026-02-17 | P2 | ITB-Med LLC | NCT04803058 A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE) | Kidney Transplantation | terminated | 7 |
| 2026-02-17 | P2 | Novartis Pharmaceuticals NVS | NCT06293365 Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled S | Sjögrens Disease; Systemic Lupus Erythematosus; Rheumatoid Arthritis | active not recruiting | 155 |
| 2026-02-18 | P3 | Pfizer PFE | NCT04821622 Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | Prostate Cancer | active not recruiting | 599 |
| 2026-02-18 | P2 | Aviceda Therapeutics, Inc. | NCT05839041 A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) | Geographic Atrophy of the Macula; Macular Degeneration | completed | 300 |
| 2026-02-18 | P3 | Celltrion | NCT06630559 A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis | Plaque Psoriasis | active not recruiting | 153 |
| 2026-02-19 | P3 | Kamada, Ltd. KMDA | NCT04204252 Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation" | Alpha 1-Antitrypsin Deficiency | terminated | 98 |
| 2026-02-19 | P2 | MacroGenics MGNX | NCT05848011 A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer | Androgen-Independent Prostatic Cancer; Androgen-Independent Prostatic Neoplasms; Prostate Cancer Rec | completed | 154 |
| 2026-02-19 | P2 | Immorna Biotherapeutics, Inc. | NCT06581575 A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine | Herpes Zoster (HZ); Infectious Diseases; Shingles | active not recruiting | 467 |
| 2026-02-20 | P1/P2 | Astellas Pharma Global Development, Inc. | NCT03288545 A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Urologic Neoplasms; Renal Pelvis Neoplasms; | terminated | 348 |
| 2026-02-20 | P2 | Iovance Biotherapeutics, Inc. IOVA | NCT03645928 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Metastatic Melanoma; Squamous Cell Carcinoma of the Head and Neck; Non-small Cell Lung Cancer | terminated | 225 |
| 2026-02-20 | P3 | Karyopharm Therapeutics Inc KPTIQ | NCT04562389 Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | Myelofibrosis | active not recruiting | 353 |
| 2026-02-20 | P2 | Mirum Pharmaceuticals, Inc. MIRM | NCT04663308 A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) | Primary Sclerosing Cholangitis | active not recruiting | 182 |
| 2026-02-20 | P1/P2 | ICM Biotech Australia Pty Ltd. | NCT04875754 A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis | Osteoarthritis, Knee | completed | 12 |
| 2026-02-20 | P3 | Novartis Pharmaceuticals NVS | NCT05648968 A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia | Warm Autoimmune Hemolytic Anemia (wAIHA) | active not recruiting | 90 |
| 2026-02-20 | P3 | mAbxience Research S.L. | NCT06596772 A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthriti | Rheumatoid Arthritis (RA) | completed | 501 |
| 2026-02-20 est. | P1/P2 | Neurodawn Pharmaceutical Co., Ltd. | NCT07166380 RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction | Transcranial Bone Marrow Injection; RK-4; Acute Large Hemispheric Infarction; Acute Ischemic Stroke | not yet recruiting | 18 |
| 2026-02-23 | P2 | Bristol-Myers Squibb BMY | NCT02719613 Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | Multiple Myeloma | completed | 67 |
| 2026-02-23 est. | P3 | Akeso | NCT04974398 A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | active not recruiting | 296 |
| 2026-02-23 | P3 | AstraZeneca AZN | NCT05301842 Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC | Hepatocellular Carcinoma | active not recruiting | 760 |
| 2026-02-23 | P2 | Janssen Research & Development, LLC | NCT05811351 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Mac | Geographic Atrophy | completed | 305 |
| 2026-02-23 | P2 | Regeneron Pharmaceuticals REGN | NCT05831176 A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side | Eosinophilic Gastritis (EoG); Eosinophilic Duodenitis (EoD); Eosinophilic Gastrointestinal Disease ( | active not recruiting | 22 |
| 2026-02-23 | P2 | Qlaris Bio, Inc. | NCT06030193 Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) | Normal Tension Glaucoma (NTG); Low-Tension Glaucoma, Bilateral; Low-Tension Glaucoma, Unspecified Ey | completed | 37 |
| 2026-02-23 | P2 | Sanofi SNY | NCT06102005 Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma | Asthma | completed | 685 |
| 2026-02-23 | P2 | NovoCure GmbH NVCR | NCT06558799 LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) | Non-Small Cell Lung Cancer (NSCLC) | terminated | 31 |
| 2026-02-23 | P2 | Avalo Therapeutics, Inc. AVTX | NCT06603077 A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | completed | 253 |
| 2026-02-23 | P2 | Suven Life Sciences Limited | NCT06836063 Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients | Major Depressive Disorder (MDD) | completed | 214 |
| 2026-02-24 | P3 | Bausch Health Americas, Inc. | NCT05297448 Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis | Hepatic Encephalopathy | completed | 517 |
| 2026-02-24 | P3 | Novartis Pharmaceuticals NVS | NCT05380453 Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission | Giant Cell Arteritis | completed | 151 |
| 2026-02-24 | P3 | Incyte Corporation INCY | NCT06113445 A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) | NonSegmental Vitiligo | active not recruiting | 467 |
| 2026-02-24 | P3 | Intra-Cellular Therapies, Inc. | NCT06462586 Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania | Bipolar Disorder, Manic | completed | 354 |
| 2026-02-24 | P3 | Haisco Pharmaceutical Group Co., Ltd. | NCT07186426 A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment in Orthopedic Surgery | Postoperative Pain Management | completed | 405 |
| 2026-02-25 | P3 | Zambon SpA | NCT04039347 Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3) | Bronchiolitis Obliterans; Obliterative Bronchiolitis; Bronchiolitis Obliterans Syndrome | terminated | 164 |
| 2026-02-25 est. | P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT04711148 A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | unknown | 160 |
| 2026-02-25 | P1/P2 | Quell Therapeutics Limited | NCT05234190 Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients | Rejection; Transplant, Liver; Liver Failure; Liver Diseases | active not recruiting | 33 |
| 2026-02-25 | P1/P2 | Amgen AMGN | NCT05975073 A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors | MTAP-null Non-Small-Cell Lung Cancer; MTAP-null Solid Tumors | completed | 53 |
| 2026-02-25 | P2 | Novartis Pharmaceuticals NVS | NCT05996835 Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI) | Acute Kidney Injury Due to Sepsis | completed | 316 |
| 2026-02-26 | P3 | Pfizer PFE | NCT05020236 A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | Multiple Myeloma | recruiting | 893 |
| 2026-02-26 | P3 | AstraZeneca AZN | NCT05742802 Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). | Chronic Obstructive Pulmonary Disease (COPD) | completed | 1713 |
| 2026-02-26 | P1/P2 | Resurge Therapeutics Inc. | NCT07264205 RT-310 Safety and Feasibility BPH Study | BPH (Benign Prostatic Hyperplasia) | active not recruiting | 20 |
| 2026-02-26 | P1/P2 | Sinovac Life Sciences Co., Ltd. | NCT07543198 Clinical Trial of PCV24 in Adults Aged ≥18 Years | Pneumococcal Infectious Disease | completed | 385 |
| 2026-02-27 | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT06134648 Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate | Respiratory Syncytial Virus Infection; Healthy Volunteers; Human Metapneumovirus | completed | 646 |
| 2026-02-27 | P2 | Ipsen | NCT06341712 Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma | Osteosarcoma; Osteosarcoma in Children; Osteosarcoma in Adolescents and Young Adults | terminated | 10 |
| 2026-02-27 | P2 | Gan and Lee Pharmaceuticals, USA | NCT06737042 Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants | Obesity and Overweight | completed | 326 |
| 2026-02-27 | P3 | Colgate Palmolive CL | NCT07263698 Investigation of Clinical Efficacy of a New Mouthwash on Reducing Dental Plaque and Helping Prevent Gum Problems as Compared to a Control Mouthwash | Gingivitis; Plaque, Dental | completed | 80 |
| 2026-02-28 | P2 | ExCellThera inc. | NCT04103879 US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia | High Risk Hematological Malignancy; Cord Blood Transplant | completed | 30 |
| 2026-02-28 est. | P1/P2 | PT. Prodia Stem Cell Indonesia | NCT05261750 Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer | Nasopharyngeal Cancer | active not recruiting | 15 |
| 2026-02-28 | P2 | Shanghai Henlius Biotech | NCT05468489 To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC | Extensive Stage Small Cell Lung Cancer | active not recruiting | 200 |
| 2026-02-28 est. | P2 | Curacle Co., Ltd. | NCT05907330 Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis | Ulcerative Colitis | unknown | 45 |
| 2026-02-28 est. | P2 | InSilico Medicine Hong Kong Limited | NCT05975983 Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | recruiting | 40 |
| 2026-02-28 est. | P1/P2 | RemeGen Co., Ltd. | NCT06038396 A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors | Advanced Solid Tumor | unknown | 48 |
| 2026-02-28 est. | P1/P2 | Keymed Biosciences Co.Ltd | NCT06126237 A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | unknown | 120 |
| 2026-02-28 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06592625 Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients | Untreated Early-stage or Locally Advanced Breast Cancer | unknown | 60 |
| 2026-02-28 est. | P2 | Guangzhou JOYO Pharma Co., Ltd | NCT06697535 A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD) | Neuromyelitis Optica Spectrum Disorders | recruiting | 35 |
| 2026-02-28 | P3 | Sarfez Pharmaceuticals, Inc. | NCT07046975 Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone | Bioavailability Heathy Volunteers | completed | 24 |
| 2026-02-28 est. | P2 | WestVac Biopharma Co., Ltd. | NCT07170800 A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets | Tuberculosis; Multidrug Resistant Pulmonary Tuberculosis; Rifampicin-resistant Tuberculosis | recruiting | 60 |
| 2026-02-28 est. | P1/P2 | Onconic Therapeutics Inc. | NCT07364422 To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer | Gastric Cancer (GC) | not yet recruiting | 49 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.